SMAD2 and breast carcinoma: Moreover, in MCF-7 and pre-malignant 4T07 breast cancer cells treated with TβRII+ EVs, we detected higher levels of TβRII and downstream phosphorylated-SMAD2 (P-SMAD2) than in cells treated with TβRII− EVs (Fig. 5a).